All In Biotech

Drug Trial Radar · NCT01227967

Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Last checked: Nov 20, 2026Latest source record: Feb 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 881 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

881

Actual

Start

Sep 2010

Primary completion

May 2, 2016

Study completion Mar 30, 2017

Sponsor

Sponsor type
NIH
First posted
Oct 25, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Seasonal influenza is responsible for many hospitalizations and deaths each year, despite effective antiviral treatments. Some individuals have medical conditions such as heart or lung diseases that make them particularly at risk of severe influenza infections that may result in hospitalization or death. Oseltamivir (Tamiflu) is used most often to treat flu, but there are still many hospitalizations, complications, and deaths even with treatment. This study evaluated the use of combination antivirals (amantadine, oseltamivir, and ribavirin) compared to oseltamivir alone in the treatment of influenza in an at-risk population.

Conditions

  • Influenza

Interventions

  • Amantadine, Ribavirin, OseltamivirDrug

    Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.

  • OseltamivirDrug

    Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) SwabsTime frame: At Day 3

Locations

91 sites in 5 countries. Site status is shown where the registry gives one.

  • Simon Williamson Clinic

    Birmingham, Alabama

  • East Valley Family Physicians

    Chandler, Arizona

  • Thomas Lenzmeier Family Practice

    Glendale, Arizona

  • Central Phoenix Medical Center

    Phoenix, Arizona

  • WCCT Global LLC

    Costa Mesa, California

  • Advanced Rx Clinical Research

    Garden Grove, California

  • Torrance Clinical Research Institute, Inc.

    Lomita, California

  • University of Southern California

    Los Angeles, California

  • University of California at San Diego

    San Diego, California

  • Westlake Medical Research (CA)

    Thousand Oaks, California

  • Los Angeles BioMedical Research Institute

    Torrance, California

  • Empire Clinical Research

    Upland, California

  • University of Colorado

    Aurora, Colorado

  • Centennial - IMMUNOe International Research

    Centennial, Colorado

  • University of Florida

    Gainesville, Florida

  • Best Quality Research Inc.

    Hialeah, Florida

  • San Marcus Research Clinic, Inc.

    Miami, Florida

  • Medical Consulting Center

    Miami, Florida

  • Suncoast Research Group, LLC

    Miami, Florida

  • University of Miami

    Miami, Florida

  • DMI Research, Inc.

    Pinellas Park, Florida

  • Northwestern University

    Chicago, Illinois

  • Sneeze, Wheeze & Itch Associates, LLC

    Normal, Illinois

  • Ridge Family Practice

    Council Bluffs, Iowa

  • University of Iowa

    Iowa City, Iowa

  • Research Integrity, LLC

    Owensboro, Kentucky

  • Horizon Research Group, of Opelousas, LLC

    Eunice, Louisiana

  • Centex Studies Inc. - Dr. Seep

    Lake Charles, Louisiana

  • NIH Clinical Center

    Bethesda, Maryland

  • Boston Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • UMass Medical School

    Worcester, Massachusetts

  • Henry Ford Health Systems

    Detroit, Michigan

  • Bronson Methodist Hospital

    Kalamazoo, Michigan

  • West Florissant Internists

    Bridgeton, Missouri

  • Clinical Research Advantage/ Skyline Medical Center

    Elkhorn, Nebraska

  • Prairie Fields Family Medicine

    Fremont, Nebraska

  • Southwest Family Physicians

    Omaha, Nebraska

  • New Jersey Medical School

    Newark, New Jersey

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.